

# **20 YEARS CLINICAL FOLLOW-UP IN PATIENTS WITH OCULOPHARYNGEAL MUSCLE DISEASE** (OPMD)

Brizzi T.<sup>1-2</sup>, Barca E.<sup>1</sup>, Biasini F<sup>1</sup>, Lupica A.<sup>1</sup>, Vita G.<sup>1</sup>, Rodolico C.<sup>1</sup>, Toscano A.<sup>1</sup>

<sup>1</sup>Department of Clinical and Experimental Medicine, University of Messina <sup>2</sup> DIBIMIS, University of Palermo

## **INTRODUCTION**

Oculopharyngeal muscle dystrophy (OPMD) is an autosomal dominant muscle disease, that is clinically characterized by ptosis, eye movement abnormalities, dysphonia and dysphagia. It is caused by an abnormal (GCN) triplet expansion within the PABPN1 gene located on chromosome 14 (14q11.2-q13). The pathologic hallmark in the disease is the accumulation of unique 8.5 nm tubulofilamentous inclusions within skeletal muscle fibers nuclei. Rimmed vacuoles of autophagic nature are also often observed in the muscle biopsy of OPMD patients.

Sex	Onset age	<b>Onset symptom</b>	GCG Expansion
F	55	ptosis, dysphonia	6/10
F	50	ptosis	6/9
Μ	60	ptosis, dysphonia, dysphagia	6/9
Μ	55	dysphagia, ptosis	6/9
F	40	ptosis	6/8
Μ	50	ptosis, dysphagia,dysph onia	6/9
F	50	ptosis, dysphagia	6/8
Μ	56	ptosis, dysphagia	6/8
F	60	ptosis	6/8
Μ	44	ptosis, dysphagia	6/11
F	46	dysphagia	6/11
Μ	45	ptosis, dysphagia	6/11
F	60	ptosis	6/9
F		asymptomatic patients	6/10
F	55	ptosis	9/9
F	56	ptosis, dysphagia	6/9
F	58	ptosis, dysphagia	6/10
F	50	ptosis, dysphagia	6/9

## **AIM OF THE STUDY**

To evaluate retrospectively natural history in a cohort of OPI

Nestle Nutrition EAT-10 Institute	0: Test per il monitoraggio della o	capacità <mark>deglutitoria</mark>
Cognome:	Nome:	Data:
Sesso:	Età:	
Obiettivo:		
Il test EAT-10 aiuta a misurare le sue Può essere importante parlare con i		ento adeguato ai suoi sintomi.
A. Istruzioni:		
Risponda ad ogni domanda barrando II v Consideri che: 0= nessun problema e 4=	valore corrispondente all'entità del sinto problema serio.	emo.
1) La difficoltà a deglutire mi ha causato una	a perdita di peso 6) Deglutire mi	causa dolore
	0 1	2 3 4
0 1 2 3 4		
	pranzare fuori casa 7) La difficoltà a	
	pranzare fuori casa 7) La difficoltà a 0 1	deglutire mi riduce il piacere del pasto
0 1 2 3 4 2) La difficoltà a deglutire mi rende difficile ( 0 1 2 3 4 3) Deglutire i liquidi mi risulta difficoltoso	0 1	

Table 1

patients with a follow-up of 5 to 20 years. A secondary goal is to better characterize the distribution muscle involvement.

## **PATIENTS AND METHODS**

✓ Since the onset of symptoms each OPMD patient underwent a neurological evaluation twice per year ✓ Clinical evaluation (MRC score) ✓ Margin Reflex Distance 1 (MRD1) ✓ Quantitative electromyography and electroneurography ✓ Muscle biopsy (12 out of 18 pts) ✓ Molecular analysis of PABPN1 gene in all patients ✓ Eating Assessment Tool (EAT-10), performed in the last 4 years follow up (fig.1)


## RESULTS

During the course of the disease the ptosis evaluated trough MRD1 worsened (fig. 2). In addition, we observed that other muscle groups, especially posterior thigh muscles were progressively affected. (fig. 3,4). EAT 10 score worsened even in patients that didn't complain for dysphagia at onset (Fig.5). All these clinical features were found in all patients except one.

In 6 out of 18 patients we found a myogenic pattern on electromyografy with normal electroneurography.

4) Deglutire cibi solidi mi risulta difficoltoso	9) Quando mangio tossisco
0 1 2 3 4	0 1 2 3 4
5) Ho difficoltà a deglutire i medicinali (pillole, compresse, capsule)	10) Deglutire mi genera ansia
0 1 2 3 4	0 1 2 3 4
B. Punteggio:	
Sommi i singoli punteggi e scriva il totale nelle caselle. Punteggio totale (massimo 40 punti)	

## **Fig. 1**







Fig. 6

p< 0,05



## **CONCLUSIONS**

Our data confirm that, at disease onset, that eyelid elevators are the most affected muscles followed by posterior thigh muscles. However, during the clinical progression, OPMD variably shows a progressive weakness of other muscle groups as posterior thigh muscles.

The EAT 10 is a valuable tool to evaluate the progressive worsening of dysphagia.

## REFERENCES

- 1. Luigetti M, Lo Monaco M, Mirabella M, Primiano G, Lucchini M, Monforte M, Servidei S. Oculopharyngeal muscular dystrophy: Clinical and neurophysiological features. Clin Neurophysiol. 2015 Dec;126(12):2406-8. doi: 10.1016/j.clinph.2015.03.005. Epub 2015 Mar 20. Review. PubMed PMID: 25842253.
- 2. Mirabella M, Silvestri G, de Rosa G, Di Giovanni S, Di Muzio A, Uncini A, Tonali P, Servidei S. GCG genetic expansions in Italian patients with oculopharyngeal muscular dystrophy. Neurology. 2000 Feb 8;54(3):608-14.



#### 3. Belafsky PC, Mouadeb DA, Rees CJ, Pryor JC, Postma GN, Allen J, Leonard RJ. Validity and reliability of the Eating Assessment Tool (EAT-10). Ann Otol Rhinol Laryngol. 2008

